Repligen Corporation Common Stock vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $421.85 (market cap $2.02T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 181.3× Repligen Corporation Common Stock's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.91% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Taiwan Semiconductor Mfg. Co. Ltd. for 111 Days on average.
| RGEN | TSM | |
|---|---|---|
Market Cap | $11.14B | $2.02T |
Volume | 1,259,263 | 8,566,236 |
Sector | Health | Technology |
52-Week High | $194.57 | $485.80 |
52-Week Low | $102.87 | $275.06 |
Typical Hold Time | 0 Days | 111 Days |
Enterprise Value | $11.02B | $1.94T |
Dividend Yield | — | 0.91% |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TSM trades at $430.00, down 3.23% on the day, with a bearish technical signal despite strong fundamentals. The company shows robust financial performance with 2025 revenue of $3.81T and net income of $1.70T, achieving 49.92% net margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $4.22 surpassing the $3.81 estimate. Analyst consensus remains strongly bullish with 72% buy ratings and a $578.43 price target, representing 34% upside potential from current levels.
TSM presents a compelling investment case driven by AI chip demand and technological leadership, though geopolitical risks and valuation concerns warrant caution. The stock's current bearish technical positioning contrasts with strong fundamentals and positive analyst sentiment, creating potential entry opportunities for long-term investors. Key risks include Taiwan-China tensions and competitive pressures in semiconductor manufacturing.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →